IL4 and asthma: Some of them are not sufficiently effective for the refractory disease (i.e. corticosteroid resistance in patients having severe asthma) and others are efficacious for specific subset of severe asthmatic patients, however, they are high-priced that precludes widespread use of those agents (e.g. biologicals that target type 2 cytokines such as IL-4, 5, 13)29,30.